6.27
+17.64%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About NextCure
From its filings with the US Securities and Exchange Commission
NextCure is based in Baltimore, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker NXTC. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2020, it reported revenue of $22.4m.
We are a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies, including antibody-drug conjugates (“ADCs”). An ADC consists of a monoclonal antibody conjugated to a cytotoxic drug via a chemical linker. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response.
Our product candidate SIM0505 is a novel ADC candidate developed by Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical, Ltd. or hereinafter “Zaiming”). We obtained (1) an exclusive, worldwide (excluding the Zaiming Territory, as identified below) license to develop, manufacture, and commercialize Zaiming’s clinical-stage ADC candidate, SIM0505, and related compounds (the “Zaiming Products”), and (2) a non-exclusive, worldwide (excluding the Zaiming Territory) license to use Zaiming’s ADC platform technology to develop ADCs based on the Company’s proprietary antibodies for an additional novel target (the “NextCure Products”) (“the License agreement”). Zaiming retained exclusive rights to develop and commercialize the Zaiming Products and any NextCure Products in China, Hong Kong, Macau, and Taiwan (the “Zaiming Territory”).
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 May 2019
- Employees
- 40
- Website
- nextcure.com ↗
- Head office
- 2850 QUARRY LAKE DRIVE, BALTIMORE, MD, 21209
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. David KabakoffIndependent Chairman of the Board$111,325
- Mr. Michael RichmanPresident, Chief Executive Officer, Director, since 2015$1.5m
- Mr. Steven CobournChief Financial Officer, since 2018$993,341
- Dr. Timothy MayerChief Operating Officer$872,206
- Mr. Kevin ShawSenior Vice President, General Counsel
- Dr. Sourav KunduSenior Vice President - Development and Manufacturing
- Dr. Solomon LangermannChief Scientific Officer$882,845
- Dr. Udayan GuhaChief Medical Officer
- Dr. Anne BorgmanIndependent Director$63,883
- Dr. Ellen FeigalIndependent Director$64,883
- Dr. John HoustonIndependent Director$67,520
- Dr. Elaine JonesIndependent Director$75,383
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 69
- Environment
- 74
- Social
- 78
- Governance
- 56
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- NextCure's FIND-IO technology identifies targets for immunomedicines in cancer and immune diseases.
- NC318 targets myeloid and tumor cells for immunotherapy treatment.
- NC410 blocks immune regulators on T cells and dendritic cells.
Weaknesses
- NextCure has 40 employees, a small team for clinical-stage biopharma.
- The company's IPO was in 2019, indicating limited market experience.
- NextCure's clinical-stage status requires significant funding for development.
Opportunities
- NextCure's FIND-IO technology can expand into autoimmunity and neurology therapeutic areas.
- The company can leverage its pipeline for unmet medical needs in cancer treatment.
- NextCure's focus on immune-related diseases aligns with growing health care demand.
Threats
- NextCure faces competition from larger biotech firms in immunotherapy development.
- Regulatory hurdles may delay clinical trials for NC318 and NC410.
- Market volatility could impact funding for NextCure's clinical-stage operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.